(Sharecast News) - Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.
The AIM-traded company said its loss for 2025 widened to £1.90m from £0.61m, with R&D expenditure rising to...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE